共 78 条
[1]
Michaud K(2007)Comorbidities in rheumatoid arthritis Best Pract Res Clin Rheumatol. 21 885-906
[2]
Wolfe F(2007)The course of established rheumatoid arthritis Best Pract Res Clin Rheumatol. 21 943-967
[3]
Scott DL(2010)Rheumatoid arthritis Lancet 376 1094-1108
[4]
Steer S(2016)2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis Arthritis Care Res (Hoboken). 68 1-25
[5]
Scott DL(2004)Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 1400-1411
[6]
Wolfe F(2004)Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind, randomised controlled trial Lancet 363 675-681
[7]
Huizinga TW(2000)Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group N Engl J Med 343 1594-1602
[8]
Singh JA(1999)Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial ATTRACT study group. Lancet. 354 1932-1939
[9]
Saag KG(2007)B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents Arthritis Rheum 56 1417-1423
[10]
Bridges SL(2012)Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR study Ann Rheum Dis 71 1861-1864